Department of Internal Medicine, Division of Hematology, Maastricht University Medical Center+, Maastricht, The Netherlands.
BMC Immunol. 2011 Feb 18;12:17. doi: 10.1186/1471-2172-12-17.
Haplo-identical hematopoietic stem cell (HSC) transplantation is very successful in eradicating haematological tumours, but the long post-transplant T-lymphopenic phase is responsible for high morbidity and mortality rates. Clark et al. have described a skin-explant system capable of producing host-tolerant donor-HSC derived T-cells. Because this T-cell production platform has the potential to replenish the T-cell levels following transplantation, we set out to validate the skin-explant system.
Following the published procedures, while using the same commercial components, it was impossible to reproduce the skin-explant conditions required for HSC differentiation towards mature T-cells. The keratinocyte maturation procedure resulted in fragile cells with minimum expression of delta-like ligand (DLL). In most experiments the generated cells failed to adhere to carriers or were quickly outcompeted by fibroblasts. Consequently it was not possible to reproduce cell-culture conditions required for HSC differentiation into functional T-cells. Using cell-lines over-expressing DLL, we showed that the antibodies used by Clark et al. were unable to detect native DLL, but instead stained 7AAD+ cells. Therefore, it is unlikely that the observed T-lineage commitment from HSC is mediated by DLL expressed on keratinocytes. In addition, we did confirm expression of the Notch-ligand Jagged-1 by keratinocytes.
Currently, and unfortunately, it remains difficult to explain the development or growth of T-cells described by Clark et al., but for the fate of patients suffering from lymphopenia it is essential to both reproduce and understand how these co-cultures really "work". Fortunately, alternative procedures to speed-up T-cell reconstitution are being established and validated and may become available for patients in the near future.
单倍体相合造血干细胞(HSC)移植在消除血液系统肿瘤方面非常成功,但移植后长期的 T 细胞减少期导致高发病率和死亡率。Clark 等人描述了一种能够产生宿主耐受的供体 HSC 衍生 T 细胞的皮肤外植体系统。由于这种 T 细胞产生平台有可能在移植后补充 T 细胞水平,我们着手验证皮肤外植体系统。
按照已发表的程序,虽然使用相同的商业组件,但无法复制用于 HSC 向成熟 T 细胞分化的皮肤外植体条件。角质形成细胞成熟程序导致具有最小 delta 样配体(DLL)表达的脆弱细胞。在大多数实验中,生成的细胞无法黏附载体或很快被成纤维细胞竞争淘汰。因此,无法复制用于 HSC 分化为功能性 T 细胞的细胞培养条件。使用过表达 DLL 的细胞系,我们表明 Clark 等人使用的抗体无法检测到天然 DLL,而是染色 7AAD+细胞。因此,观察到的 HSC 向 T 细胞系的定向分化不太可能是由角质形成细胞上表达的 DLL 介导的。此外,我们确实证实了角质形成细胞表达 Notch 配体 Jagged-1。
目前,令人遗憾的是,Clark 等人所描述的 T 细胞的发展或生长仍然难以解释,但对于遭受淋巴细胞减少症的患者的命运而言,复制和理解这些共培养物的实际“工作原理”至关重要。幸运的是,正在建立和验证加速 T 细胞重建的替代程序,并可能在不久的将来为患者提供。